LGVN - Longeveron inks contract with US Veterans Affairs for phase 2 Alzheimer's trial

Longeveron (NASDAQ:LGVN) signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) for the addition of a Miami VA clinical site to its ongoing phase 2 Alzheimer’s Disease (AD) trial. The phase 2 trial, dubbed CLEAR MIND, consists of four treatment arms of 12 patients each, with total target enrollment of 48 patients. The study will investigate safety and tolerability, and secondary goals, including cognitive function and biomarkers, following single or multiple infusions of Lomecel-B compared to placebo in people with mild AD. The company said its phase 1 trial had met the main goal, showing that its drug Lomecel-B was well tolerated in patient with AD. The company noted that this marks the third separate CRADA between the VA and Longeveron, including an Aging Frailty study and an ongoing study on COVID-19.

For further details see:

Longeveron inks contract with US Veterans Affairs for phase 2 Alzheimer’s trial